What Fueled The Previous Growth In The Urokinase Market?
The urokinase market has seen considerable growth due to a variety of factors.
• In recent times, there has been robust growth in the urokinase market size. The market is set to expand from $1.7 billion in 2024 to $1.81 billion in 2025, with a compound annual growth rate (CAGR) of 6.0%.
Factors contributing to this growth during the historic period include a rise in stroke and heart attack cases, increased clinical research, regulatory consents for crucial indications, creation of initial formulations, and an expanding healthcare infrastructure.
What Is The Expected Growth In The Urokinase Market Size Evolve over the Forecast Period?
The urokinase market is expected to maintain its strong growth trajectory in upcoming years.
• In the ensuing years, robust growth is anticipated for the urokinase market, which is projected to escalate to $2.26 billion by 2029 with a CAGR of 5.7%.
The anticipated growth during this period is fuelled by factors such as the rising focus on individualized medicine, an increased occurrence of pulmonary embolism, mounting investments in cardiovascular and stroke research, advances in diagnostic and imaging methodologies, an aging population, and a surge in obesity rates. Major forecasted market trends entail enhancements in customized medicine, the technological evolution in drug delivery systems, the introduction of AI and digital healthcare tools, progression in digital health platforms, and advances in clinical research.
What Main Forces Are Fueling Expansion In The Urokinase Market?
Anticipated growth of the urokinase market is largely attributed to the escalating prevalence of cardiovascular diseases. Cardiovascular diseases, also known as CVDs, encompass a variety of conditions that affect the heart and blood vessels, including heart attack, stroke and high blood pressure. These are becoming increasingly common due to several factors including increased rates of obesity, lack of physical exercise, unhealthy diets, and a rapidly aging population. Urokinase plays an instrumental role in minimizing the impact of these diseases by breaking up the blood clots that block blood flow, helping to prevent strokes and heart attacks, restoring normal blood circulation and reducing further cardiovascular harm. Take for example, a report published by the American College of Cardiology, a US-based medical association, in August 2022. The report forecasts that, in the United States, every one of the four primary cardiovascular risk factors will significantly rise between 2025 and 2060. Diabetes is expected to experience the highest percentage increase of 39.3%, affecting 55 million individuals. It also predicts significant increases in stroke rates (33.8% to 15 million), heart failure (33.4% to 13 million), ischemic heart disease (30.7% to 29 million) and heart attacks (16.9% to 16 million). Therefore, it is clear that the rising prevalence of cardiovascular diseases is a major propellant in the growth of the urokinase market.
What Are The Primary Segments In The Global Urokinase Market?
The urokinasemarket covered in this report is segmented –
1) By Type: Urokinase Powder, Urokinase Solution
2) By Manufacturing Process: Biotechnological Methods, Traditional Extraction
3) By Indication: Catheter Clearance, Coronary Artery Thrombosis, Deep Vein Thrombosis, Pulmonary Embolism
4) By Distribution channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By Application: Hospital, Clinics, Other Applications
Subsegments:
1) By Urokinase Powder: Pharmaceutical-Grade Urokinase Powder, Research-Grade Urokinase Powder, Recombinant Urokinase Powder
2) By Urokinase Solution: Injectable Urokinase Solution, Infusion Urokinase Solution, Pre-mixed Urokinase Solution
Pre-Book The Urokinase Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Market Trends Are Altering The Urokinase Industry?
Significant players in the urokinase market are re-launching and marketing medical products for novel uses to increase the effectiveness of treatment, competitive standing in the market, and make it more accessible to patients. This practice of re-launching and marketing a medical product for new uses entails the revival of a formerly accessible or discontinued drug for the treatment of new diseases and implementing strategies for its successful distribution, sales, and marketing. To illustrate, MBX Biosciences, a biopharmaceutical company based in the U.S., in May 2023, teamed up with Sequel Pharma LLC, another U.S.-based pharmaceutical company, to re-launch and sell kinlytic urokinase. This partnership is aimed at boosting its reach in the catheter clearance market and increasing the effectiveness of treatment for patients. This partnership underscores the trend of using strategic partnerships to effectively resurrect and advertise medical products, making sure they fulfil present market demands and regulatory standards.
Who Are the Key Players In The Urokinase Market?
Major companies operating in the urokinase market are:
• Thermo Fisher Scientific Inc.
• Mochida Pharmaceutical Co. Ltd.
• Bharat Serums and Vaccines Limited
• Taj Pharmaceuticals Ltd.
• TTK Health Care Limited
• Agrata Biotech Limited
• Cerbios-Pharma SA
• Microbix Biosystems Inc.
• Midas Pharma GmbH
• ImaRx Therapeutics
• Health Biotech Limited
• Salvavidas Pharmaceutical Pvt. Ltd.
• BBT Biotech GmbH
• Syner-Med (Pharmaceutical Products) Ltd.
• Echelon Biosciences Inc.
• Kraeber & Co GmbH
• Samarth Life Science Pvt. Ltd.
• WUHAN HANWEISHI PHARMCHEM CO. LTD.
• Aetos Pharma
• MITS CRITICAL CARE
What Is The Most Dominant Region In The Urokinase Market?
North America was the largest region in the urokinase market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the urokinase market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
